<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03936699</url>
  </required_header>
  <id_info>
    <org_study_id>CD-005</org_study_id>
    <nct_id>NCT03936699</nct_id>
  </id_info>
  <brief_title>ELIRA 2: Safety and Effectiveness of TENS Assisted Weight Loss and Appetite Suppression</brief_title>
  <acronym>ELIRA_2</acronym>
  <official_title>Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss and/or Appetite Suppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elira Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Elira Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to demonstrate safety and effectiveness of a wearable patch&#xD;
      TENS system (Appendix 2) in driving weight loss and appetite suppression when coupled with an&#xD;
      integrated weight loss reduction strategy. The study is designed to demonstrate that TENS&#xD;
      stimulation sufficient to drive weight loss and appetite suppression is safe and tolerable&#xD;
      when compared to standard of care, and that adverse events/adverse device effects are similar&#xD;
      to other TENS device use cases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, adaptive parallel arm study. Subjects will be initially screened during a&#xD;
      screening period (+/- 7 days). During this screening period, subjects will sign an Informed&#xD;
      Consent Form (ICF), have their weight/height and blood pressure measured as part of a&#xD;
      physical exam, take a pregnancy test (females of child bearing potential), get blood drawn&#xD;
      for analysis (blood lipids, HbA1c), and complete the PHQ-9 and pre-study survey.&#xD;
&#xD;
      At the end of the screening period, eligible subjects will be enrolled/randomized in the&#xD;
      study and be randomized to either a treatment or control group. After enrolling, both control&#xD;
      and treatment subjects will be instructed to follow a healthy diet and reduce calories as&#xD;
      desired for the duration of the study and will receive training on the use of the electronic&#xD;
      scale and completion of paper diaries. For the treatment group, subjects will be instructed&#xD;
      on use of the Elira wearable patch system. Photographs will be taken at the enrollment visit.&#xD;
      Following this, subjects will enter the Therapy Period for ~24-weeks.&#xD;
&#xD;
      At the 12 week visit, subjects will be assessed for weight loss, blood pressure, blood&#xD;
      lipids, HbA1c, patient preference questionnaire and their participation will continue through&#xD;
      months 4-6 for the Safety phase of the Therapy Period. The Therapy Period will be considered&#xD;
      complete (pending laboratory results, adverse events or serious adverse events). Patient&#xD;
      (treatment) photographs will also be taken at the 12 week visit.&#xD;
&#xD;
      The study utilizes an adaptive approach where cohorts of enrolled/randomized subjects (in&#xD;
      groups of ~25 per arm) are assessed for dose response and progression to achievement of&#xD;
      primary and secondary endpoints. Frequent interim endpoint assessment utilizing Markov-chain&#xD;
      Monte Carlo (MCMC) methods coupled with Longitudinal analyses will be utilized to determine&#xD;
      sample sizes for future cohorts (assessed primarily via Normal dynamic linear modeling&#xD;
      [NDLM]). Long term safety of the device will be shown through 6 months of usage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 22, 2018</start_date>
  <completion_date type="Actual">May 30, 2019</completion_date>
  <primary_completion_date type="Actual">May 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, adaptive parallel arm study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Emergent Adverse Events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Treatment Emergent Adverse Events [Time Frame: 12 weeks] Safety/Tolerability will be assessed by the non-inferiority of incidence of serious adverse events (SAEs), unanticipated serious adverse events (USAEs), device-related SAEs (DSAEs), and unanticipated device-related SAEs (UDAEs) that are associated with the TENS therapy throughout the stimulation and the follow-up period versus historical control (compared with other TENS systems).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in appetite as measured by a visual analogue scale before and after meals</measure>
    <time_frame>3 months</time_frame>
    <description>Appetite Changes [Time Frame: 12 weeks] Percent change in appetite scores at the end of the trial compared to Baseline between Treatment and Control.&#xD;
Subjects are asked to score level of hunger on a Visual Analogue Scale of 1 to 100 before and after meals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Percent Total Body Weight Loss</measure>
    <time_frame>3 months</time_frame>
    <description>Percent reduction in total body weight loss (%TBWL), measured as End Weight - Initial Weight, multiplied by 100, at the end of Experimental period compared to Baseline between Treatment and Control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in BMI</measure>
    <time_frame>3 months</time_frame>
    <description>Percent changes in BMI at the end of Experimental period compared to Baseline between Treatment and Control.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>Weight Loss</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Transcutaneous Nerve Stimulator (TENS) Elira wearable patch system will be applied to varying locations on the T6/T7 dermatome for 30 minutes three times a day after meals. Subjects will be instructed to follow a 1200 calorie healthy diet and record any changes in appetite.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Open label diet and exercise counseling only. Subjects will be instructed to follow a healthy 1200 calorie diet and record any changes in appetite.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcutaneous Nerve Stimulator (TENS)</intervention_name>
    <description>The Elira wearable patch system is a Radio Frequency (RF) coupled, wearable transcutaneous electrical nerve stimulator (TENS) device controlled via Bluetooth by a smart phone unit running a custom application which directs therapy from the patch within safe limits set by a clinician and also includes a weight loss diary.&#xD;
Behavioral: Diet &amp; Exercise Subjects to be instructed on a healthy 1200 calorie diet.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Diet &amp; Exercise</intervention_name>
    <description>Subjects to be instructed on a healthy 1200 calorie diet.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is between 18 - 65 years of age inclusive.&#xD;
&#xD;
          2. Subject has a BMI of 25-35 kg/ m2 inclusive.&#xD;
&#xD;
          3. Subject has signed the informed consent form and is able to comply with study protocol&#xD;
             and adhere to study visit schedule.&#xD;
&#xD;
          4. Subject is able to wear and use a wearable, patch TENS system.&#xD;
&#xD;
          5. Subject is able to use a touch screen hand held smart phone.&#xD;
&#xD;
          6. Subject is fluent in English and can complete questionnaires.&#xD;
&#xD;
          7. Females of childbearing potential (FOCBP) must have a negative urine pregnancy test at&#xD;
             screening or enrollment visit, prior to placement of ELIRA device.&#xD;
&#xD;
          8. Subject is male or non-pregnant, non-lactating female, who agrees to use effective&#xD;
             contraceptive methods throughout the length of the trial based on PI approval.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has any known gastrointestinal disorder that in the opinion of the PI&#xD;
             precludes enrollment into the trial.&#xD;
&#xD;
          2. Subject has had a prior bariatric procedure or any previous procedure on the stomach.&#xD;
&#xD;
          3. Subject has any significant multisystem disease in the opinion of the PI.&#xD;
&#xD;
          4. Subject has &gt; 6.5 HbA1c.&#xD;
&#xD;
          5. Subject has significant cardiac arrhythmia, ectopy, or significant cardiovascular&#xD;
             disease.&#xD;
&#xD;
          6. Subject has an existing implanted electrical stimulator (e.g., pacemaker, AICD).&#xD;
&#xD;
          7. Subject is a female of child-bearing potential who is pregnant or intends to become&#xD;
             pregnant during the trial period.&#xD;
&#xD;
          8. Subject has current and/or a history of cancer within the past 5 years (not including&#xD;
             basal cell carcinoma or cervical carcinoma in situ).&#xD;
&#xD;
          9. Subject has had a weight change of + 5% of his/her Total Body Weight in the 3 months&#xD;
             prior to screening.&#xD;
&#xD;
         10. Subject has a moderate / severe psychiatric disorder.&#xD;
&#xD;
         11. Subject has a diagnosed neurological disease.&#xD;
&#xD;
         12. Subject has a diagnosed eating disorder.&#xD;
&#xD;
         13. Subject has a skin disorder affecting the thoracic dermatomes.&#xD;
&#xD;
         14. Subject has active or /has ever had shingles in the abdominal area.&#xD;
&#xD;
         15. Subject has abdominal surgery or other scars which may interfere with TENS stimulation&#xD;
             in the opinion of the PI.&#xD;
&#xD;
         16. Subject is currently enrolled in other potentially confounding research.&#xD;
&#xD;
         17. Subject has known allergic reaction to materials in the TENS electrodes and/or is&#xD;
             otherwise unable to tolerate stimulation with the wearable TENS system. This includes&#xD;
             known allergies to latex, nickel and/or hydrogels.&#xD;
&#xD;
         18. Subject has a history of sensitive skin, including eczema wheel-and-flare or other&#xD;
             skin irritation, per PI discretion.&#xD;
&#xD;
         19. Subject is actively participating or unwilling to discontinue participation in another&#xD;
             weight loss program. Subjects may not enroll in paid or unpaid programs that involve&#xD;
             in-person or online apps or coaching, beginning new fitness regimens or utilizing meal&#xD;
             planning or paid nutritional coaching during the course of the ELIRA study&#xD;
&#xD;
         20. Subject is taking weight loss control medications including but not limited to Over&#xD;
             The Counter (OTC) medications, Metformin, and Belviq. (See Appendix 8)&#xD;
&#xD;
         21. Subject is planning any major medical treatments or surgeries that could cause weight&#xD;
             loss.&#xD;
&#xD;
         22. Subject is unable to take anti-nausea medications planned for the study.&#xD;
&#xD;
         23. Inability to walk at least 0.8 kilometers per day (10 minutes of continuous walking).&#xD;
&#xD;
         24. Current smoker or user of nicotine product or smoking cessation within 1 year of the&#xD;
             screening date.&#xD;
&#xD;
         25. History of treatment for or current abuse of drug or alcohol.&#xD;
&#xD;
         26. A score of â‰¥10 on the Patient Health Questionnaire 9 (PHQ-9), demonstrating moderate&#xD;
             depression.&#xD;
&#xD;
         27. Any subject that the investigator considers inappropriate for the study for medical&#xD;
             reasons.&#xD;
&#xD;
         28. Subject has a history of moderate/severe migraines or other severe headache disorders&#xD;
             requiring the treatment of Topiramate.&#xD;
&#xD;
         29. Subject is on drug therapy which may alter antral motility or appetite, per PI&#xD;
             discretion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>West County OB/GYN Specialists</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 29, 2018</study_first_submitted>
  <study_first_submitted_qc>May 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2019</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>October 25, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

